Gavreto (Pralsetinib)

Gavreto is a kinase inhibitor used for the treatment of adult patients with metastatic RET fusion- positive non-small cell lung cancer (NSCLC). 

Recommended Dosage: The recommended dosage is 400 mg orally once daily on an empty stomach (no food intake for at least 2 hours before and at least 1 hour after taking your dose). Continue treatment with Gavreto (Pralsetinib Capsules) until disease progression or until unacceptable toxicity. In case a dose of Pralsetinib is missed, it can be taken as promptly as possible on the same day. Regular daily dose schedule needs to be resumed the next day. Avoid taking an additional dose in case vomiting occurs but continue with the next dose as scheduled. 

• Withhold Pralsetinib 100 mg Capsules for Grade 1/2 reactions until the time of resolution and then resume at a reduced dose. Permanently discontinue for the recurrent ILD/pneumonitis.
• Do not initiate therapy with Pralsetinib in patients with uncontrolled hypertension. Optimize BP prior to initiating Pralsetinib therapy. Monitor BP after 7 days, at least monthly thereafter.
• Monitor ALT & AST before initiating Gavreto 100 mg capsules, every 14 days during the first 3 months, then monthly thereafter. Withhold, reduce dose, or permanently discontinue on behalf of severity.
• Permanently discontinue the treatment with capsules of Pralsetinib in patients with severe or life-threatening hemorrhage.
• Withhold the Gavreto capsules for at least 5 days before elective surgery. Avoid administering for at least 14 days following major surgery and until adequate wound healing. 
• Gavreto therapy can cause fetal harm. Advise womens of reproductive age of the potential risk to a fetus and to consider effective non-hormonal contraception. 

What documents are required to import GAVRETO to India?

GAVRETO (Pralsetinib) can be imported by patients or government hospitals in the name of the patients only.

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients ID proof (issued by the government of India)

How does the order confirm?

The order will be confirmed only after the receipt of:

• A valid prescription from a doctor
• Import permit if applicable

Is GAVRETO available in India?

GAVRETO (Pralsetinib Capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

Urgent Meds helps import cancer medicines on the named patient supply (NPS). Urgent Meds is a facilitator providing input on:

• Availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune, etc.)
• Medicine Price
• Finding genuine and reliable sources from Canada, Europe, USA, and Australia
• Ensuring 100% transparency

GAVRETO (Pralsetinib Capsules) can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

Urgent Meds can facilitate the supply of GAVRETO (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +1-647-818-4196 or write us at info@urgentmeds.in

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Urgent Meds is able to source GAVRETO (Cancer Treatment Medicines) from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Gavreto® ?

Pralsetinib is the Generic Name for the trade name drug Gavreto®.

What is the Manufacturer Name of Gavreto®?

Gavreto® is manufactured by Genentech, Inc.

Is Gavreto® approved by the FDA?

Yes, Gavreto® is approved by the FDA. Date of approval: December 1, 2020.

What is Gavreto®?

Gavreto® is a once-daily oral targeted therapy for people living with RET+Ve (RET+) metastatic NSCLC or advanced thyroid cancer.

What is the dosage and form of Gavreto® available?

Gavreto® is available as Capsules: 100 mg for oral administration.

How does Pralsetinib work?

Pralsetinib falls under the group of medications called antineoplastics (cancer medicines). It works by interfering with the growth of malignant cells, which are eventually destroyed.

Is it safe to buy Gavreto® (Pralsetinib Capsules) online?

Yes, in order to buy Pralsetinib Capsules online, always look for an authentic and WHO-GDP & ISO certified pharmaceutical wholesaler/distributor/supplier.

What are the most common side effects due to Gavreto®?

The most common side effects due to Gavreto® include fatigue, constipation, hypertension, and musculoskeletal pain.

What are the storage conditions of Gavreto®?

Store the capsules at a temperature of 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F). Protect from moisture.

How much does Gavreto® cost in India?

You can call or WhatsApp +1-647-818-4196 or send mail to info@urgentmeds.in to know the cost of Pralsetinib 100 mg Capsules in India.